Michaela Liedtke

Feb 13, 2023 | futuremedicine.com | Barry Paul |Michaela Liedtke |Jack Khouri |Robert Rifkin

Future OncologyAhead of PrintClinical Trial ProtocolOpen Access, , , , , , , , , , , , , , , & AbstractMagrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me’ signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in elimination of myeloma cells, and that there is synergy between magrolimab and certain anticancer therapies.